
EBR Systems, Inc.
@EBRSystemsInc
Followers
340
Following
96
Media
123
Statuses
189
Leadless LV endocardial pacing for patients with heart failure.
Sunnyvale, CA
Joined September 2018
🎉 FDA-approved now: The WiSE System is here. The first system to deliver leadless LV endocardial pacing (LVEP)—pacing the left ventricle from inside the heart. It’s CRT without the limits—and finally, an option for the patients left behind.
prnewswire.com
/PRNewswire/ -- EBR Systems, Inc. (ASX: EBR) has received FDA approval of the WiSE® System, which marks a significant leap forward in the treatment of heart...
1
3
8
RT @FogartyInnov: Congratulations to Fogarty company-in-residence, @Materna_Medical on the completion of a recent close within an ongoing $….
0
2
0
RT @StockheadAU: Vital Signs Podcast: @EBRSystemsInc major milestones in WiSE CRT commercialisation #ASX #Medtech $….
0
1
0
Vital Signs Podcast: EBR’s major milestones in WiSE CRT commercialisation
stockhead.com.au
In the episode, we unpack EBR Systems' (ASX:EBR) major milestones this year and next steps in the commercial roll out of its tech.
0
3
6
First U.S. commercial implants of the FDA-approved WiSE System are complete—thanks to.🫀 Dr. Robert Canby + team at @StDavidsHC.🫀 Dr. Niraj Varma @ClevelandClinic.Leadless LVEP is here for heart failure patients who had no other options. Press Release:
prnewswire.com
/PRNewswire/ -- In a major milestone for heart failure treatment, the first commercial patients in the U.S. have been successfully implanted with the...
1
2
11
RT @StockheadAU: Break it Down: @EBRSystemsInc completes first US commercial implants of WiSE CRT system. Watch the video here: https://t.….
0
1
0
RT @FogartyInnov: Please share this opportunity with colleagues and friends! The Fogarty Prize recognizes an individual or team who has dev….
0
1
0
EBR Systems President and CEO John McCutheon joins Fraser Palamara on Stockhead TV to talk about the company’s recent FDA submission.
stockhead.com.au
EBR Systems (ASX:EBR) President and CEO John McCutheon on Stockhead TV talks about the company's recent FDA submission.
0
1
8